A group of seven related reporting persons led by Venrock Healthcare Capital Partners filed a Schedule 13G with the SEC disclosing beneficial ownership of 700,000 Class A Ordinary Shares of Frazier Life Sciences Acquisition Corp. II, with the triggering event dated October 15, 2026.

Key Highlights

  • Total beneficial ownership: Each reporting person beneficially owns 700,000 Class A Ordinary Shares, representing 9.0% of the class.
  • Share breakdown: Holdings consist of 318,150 shares held by VHCP III, 31,850 shares held by VHCP Co-Investment III, and 350,000 shares held by VHCP EG, according to the filing.
  • Shares outstanding: The percentage is based on 7,800,000 Class A Ordinary Shares outstanding as of October 15, 2026, as reported in the issuer's final prospectus dated October 13, 2026.
  • Voting and dispositive power: All 700,000 shares are held with shared voting and shared dispositive power; sole voting and sole dispositive power are each reported as 0.
  • Reporting persons: The group comprises seven parties: Venrock Healthcare Capital Partners III, L.P.; VHCP Co-Investment Holdings III, LLC; Venrock Healthcare Capital Partners EG, L.P.; VHCP Management III, LLC; VHCP Management EG, LLC; Nimish Shah; and Bong Y. Koh.
  • Control structure: According to the filing, VHCP Management III is the general partner of VHCP III and manager of VHCP Co-Investment III; VHCP Management EG is the general partner of VHCP EG; Shah and Koh are the voting members of both management entities.

Venrock Healthcare Group Discloses Position in Frazier Life Sciences Acquisition Corp. II

Seven related reporting persons filed a Schedule 13G disclosing a collective position in Frazier Life Sciences Acquisition Corp. II, a company whose Class A Ordinary Shares carry a par value of $0.0001 per share (CUSIP: G37103101). The filing states the date of the event requiring the statement was October 15, 2026, with the issuer's principal executive offices located at 1001 Page Mill Road, Building 4, Suite 200B, Palo Alto, CA.

According to the filing, the 700,000 Class A Ordinary Shares are distributed across three investment vehicles: 318,150 shares held by Venrock Healthcare Capital Partners III, L.P.; 31,850 shares held by VHCP Co-Investment Holdings III, LLC; and 350,000 shares held by Venrock Healthcare Capital Partners EG, L.P. Each of the seven reporting persons, including individuals Nimish Shah and Bong Y. Koh, is attributed the full 700,000 share total and the same 9.0% ownership figure, reflecting the shared control and dispositive structure described in the filing.

The filing states that the percentage of class is calculated based on 7,800,000 Class A Ordinary Shares outstanding as of October 15, 2026, as reported in the issuer's final prospectus dated October 13, 2026, filed with the SEC on October 14, 2026. All entities were organized in Delaware; Shah and Koh are identified as United States citizens. The reporting persons are described as members of a group for the purposes of this Schedule 13G, with offices in New York, NY and Palo Alto, CA.

What Was Disclosed

A Schedule 13G was filed disclosing that a seven-member group including Venrock Healthcare Capital Partners III, L.P. and affiliated entities and individuals collectively hold 700,000 Class A Ordinary Shares of Frazier Life Sciences Acquisition Corp. II, representing 9.0% of the class as of October 15, 2026.